Why Analysts Are Rewriting the Zscaler Story After Fresh Results and Guidance

Zscaler's price target has seen a slight uptick following new earnings and guidance, climbing from $327.98 to $328.22. This increase comes as analysts weigh the company's strong performance in new ...

Cathie Wood buys $56 million of megacap tech stock

Cathie Wood, head of Ark Investment Management, is best known for betting on early-stage tech names and high-growth ...
JCN Newswire

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...

Eisai Completes Rolling Submission to US FDA for LEQEMBI (R) IQLIK (TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early ...
JCN Newswire

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...